The Primary objective of this study is to evaluate the safety and biochemical efficacy of single escalating doses of Ad2/CFTR-2 (adenovirus- based Vector encoding the cystic fibrosis transmembrane conductance regulator) aerosolized to the lungs of cystic fibrosis patients. To achieve this objective while assessing and minimizing potential risks associated with delivery of Ad2/CFTR-2 will be delivered (through a bronchoscope) to a single lobe of the lung of cystic fibrosis patients prior to aerosolizing the same dose to the lung.
Showing the most recent 10 out of 412 publications